Synta Pharmaceuticals Corp. has initiated a Phase II trial of STA-9090, a potent, synthetic, small molecule Hsp90 inhibitor, in patients with advanced gastrointestinal stromal tumors (GIST). “We and our collaborators have been encouraged by the strong preclinical results for STA-9090 in GIST as well as early results from our solid tumor Phase I trials, where STA-9090 has generated objective tumor responses and has been well-tolerated, with the most common adverse events, fatigue and gastroin...